Cameron E. West

Cameron E. West

Auto-generated profile, based on publicly available information

Cameron E. West

Department of Dermatology and Pathology, Texas Tech University, Abilene, TX 79601, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LBLaurence Booth
Laurence Booth
JRJane L. Roberts
Jane L. Roberts
CWCameron West
Cameron West
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
Paul DentPaul Dent
Paul Dent

2 September 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LBLaurence Booth
Laurence Booth
CWCameron West
Cameron West
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
Paul DentPaul Dent
Paul Dent
GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate ATM and c-MET, inactivate mTOR, AKT, and p70 S6K, enhance the expression of Beclin1 and reduce the levels of K-RAS and N-RAS. This was followed later by the drugs interacting to reduce expression of MCL-1, BCL-XL, and HDAC6. Knock down of ATM prevented the drugs alone or in combination inactivating mTOR or activating ULK1. Knock down of c-MET significantly enhanced [doxorubicin + 602] lethality. Knock down of ATM and to a greater extent ULK1, Beclin1, or ATG5 significantly reduced killing by 602 alone or when combined with doxorubicin. Expression of an activated mTOR mutant suppressed killing, autophagosome formation and prevented autophagic flux. In the absence of Beclin1, knock down of CD95, or FADD, or over-expression of c-FLIP-s or BCL-XL abolished tumor cell killing. We conclude that 602 and doxorubicin interact to increase autophagosome formation and autophagic flux as well as causing elevated death receptor signaling resulting in mitochondrial dysfunction and tumor cell death.

1 January 2015 in Dermatology Online Journal
Verified
Journal Article
Open access
PDF file
CNColton Nielson
Colton Nielson
CWCameron West
Cameron West
ISIkue Shimizu
Ikue Shimizu
The inherently visual nature of dermatology naturally lends itself to photography. As technology has evolved, smartphone cameras have become ubiquitous and have the potential to improve education and patient care in dermatology. Although patients and physicians may agree that photography can improve patient care, there are certain risks involved with smartphone photography in the medical field. Perhaps most concerning is the number of dermatologists using smartphones to take unsecured images in their daily practice. A recent study revealed that 22% of surveyed dermatologists used smartphone cameras multiple times per day in their practice. Dermatologists may also overestimate patient comfort with smartphone use in clinical photography. We present a review of the use of smartphones in dermatology and address the potential lack of security and accompanying ethical dilemmas.Keywords: Smartphone, iPhone, digital

23 March 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
CWCameron E. West
Cameron E. West
AWAshleigh Workman
Ashleigh Workman
TMTricia Moody
Tricia Moody
GHGregory A. Hosler
Gregory A. Hosler

28 December 2021 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
APAllie Preston
Allie Preston
CWCameron West
Cameron West
MMMartha McCollough
Martha McCollough
GHGregory A. Hosler
Gregory A. Hosler
Panfolliculomas (PF) are rare, benign, follicular tumors that differentiate toward multiple components of the hair follicle, and several variants have been described. We present a case of a rare pigmented PF presenting on actinically damaged skin in an 83-year-old man, which was clinically concerning for malignancy. This tumor arose near an area of atypical squamous proliferation and has evidence of infundibular, outer root sheath, and matrical differentiation and foci of heavy melanin pigmentation and increased melanocytes. We propose the novel designation of “melanocytic PF,” akin to melanocytic matricoma but with panfollicular differentiation.

4 February 2022 in Oncotarget
Verified
Journal Article
Open access
PDF file
LBLaurence Booth
Laurence Booth
CWCameron West
Cameron West
RMRobert p Moore
Robert p Moore
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
Paul DentPaul Dent
Paul Dent
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Laurence Booth1, Cameron West2, Robert P. Moore2, Daniel Von Hoff3 and Paul Dent1 1 Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA 2 Genzada Pharmaceuticals, Sterling, KS 67579, USA 3 Physician-in-Chief, Distinguished Professor, Translational Genomics Research Institute (TGEN), Phoenix, AZ 85004, USA Correspondence to: Paul Dent, email: paul.dent@vcuhealth.org Keywords: GZ17-6.02; axitinib; renal cell carcinoma; autophagy; HDAC Received: December 09, 2021 Accepted: January 25, 2022 Published: February 04, 2022 Copyright: © 2022 Booth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. The present studies were performed to define its biology in renal carcinoma cells and to determine whether it interacted with axitinib to enhance tumor cell killing. GZ17-6.02 interacted in an arithmetically greater than additive fashion with axitinib to kill kidney cancer cells. GZ17-6.02 and axitinib cooperated to inactivate ERBB2, c-MET, c-KIT, c-SRC, the AMPK, STAT3, STAT5 and eIF2α and to activate PERK, ULK1 and ATG13. The drugs interacted to increase the expression of FAS-L and to decrease the levels of MCL1, BCL-XL, and HDACs 1–3. The drugs as single agents inactivated the Hippo pathway. GZ17-6.02 and axitinib interacted to enhance autophagosome formation and autophagic flux. Knock down of Beclin1, ATG5, eIF2α, toxic BH3 domain proteins or CD95/FADD significantly reduced drug combination lethality. GZ17-6.02 and axitinib increased the expression of BAK, BIM, Beclin1 and ATG5, effects blocked by knock down of eIF2α. The drugs increased phosphorylation of ULK1 S757 and ATG13 S318 and decreased the phosphorylation of mTORC1 and mTORC2, effects blocked by knock down of AMPKα. Knock down of Beclin1 or ATG5 prevented the drug combination reducing expression of HDACs 1–3 and from enhancing the expression of MHCA. Knock down of HDACs 1–3 enhanced MHCA expression. We conclude that GZ17-6.02 and axitinib interact to kill requiring ER stress signaling, autophagy and death receptor signaling. Autophagic degradation of HDACs played a key role in enhancing MHCA expression and of a potential improved response to checkpoint inhibitory immunotherapy. <!--x2o[c3ff2785]-->